-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Buy on Janux Therapeutics, Raises Price Target to $27

Benzinga·11/06/2026 18:13:26
Listen to the news
Truist Securities analyst Supawat Thongthip maintains Janux Therapeutics (NASDAQ:JANX) with a Buy and raises the price target from $26 to $27.